Allo-reactive T cells for the treatment of hematological malignancies

Molecular Oncology

Volumn 9, Issue 10, 2015, Pages 1894-1903

  Falkenburg, J H F ^a   Jedema, I ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allogeneic stem cell transplantation; Hematological malignancies; Immune therapy; T cells

Indexed keywords

HLA ANTIGEN CLASS 2; MINOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CROSS REACTION; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HLA SYSTEM; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY;

HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOTHERAPY; T-LYMPHOCYTES;

EID: 84952638643     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.10.014     Document Type: Review

References (85)

1. Abrahamsen I.W., Stronen E., Walchli S., Johansen J.N., Kjellevoll S., Kumari S., Komada M., Gaudernack G., Tjonnfjord G., Toebes M., Schumacher T.N., Lund-Johansen F., Olweus J. Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia 2010, 24:1901-1909.
2. Akatsuka Y., Nishida T., Kondo E., Miyazaki M., Taji H., Iida H., Tsujimura K., Yazaki M., Naoe T., Morishima Y., Kodera Y., Kuzushima K., Takahashi T. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J. Exp. Med. 2003, 197:1489-1500.
3. Alexander-Miller M.A., Burke K., Koszinowski U.H., Hansen T.H., Connolly J.M. Alloreactive cytotoxic T lymphocytes generated in the presence of viral-derived peptides show exquisite peptide and MHC specificity. J. Immunol. 1993, 151:1-10.
4. Amir A.L., D'Orsogna L.J., Roelen D.L., van Loenen M.M., Hagedoorn R.S., de B.R., Van Der Hoorn M.A., Kester M.G., Doxiadis I.I., Falkenburg J.H., Claas F.H., Heemskerk M.H. Allo-HLA reactivity of virus-specific memory T-cells is common. Blood 2010, 115:3146-3157.
5. Amir A.L., van der Steen D.M., Hagedoorn R.S., Kester M.G., van Bergen C.A., Drijfhout J.W., de Ru A.H., Falkenburg J.H., van Veelen P.A., Heemskerk M.H. Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. Blood 2011, 118:6733-6742.
6. Amir A.L., van der Steen D.M., van Loenen M.M., Hagedoorn R.S., de B.R., Kester M.D., de Ru A.H., Lugthart G.J., van K.C., Hiemstra P.S., Jedema I., Griffioen M., van Veelen P.A., Falkenburg J.H., Heemskerk M.H. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clin. Cancer Res. 2011, 17:5615-5625.
7. Aosai F., Ohlen C., Ljunggren H.G., Hoglund P., Franksson L., Ploegh H., Townsend A., Karre K., Stauss H.J. Different types of allospecific CTL clones identified by their ability to recognize peptide loading-defective target cells. Eur. J. Immunol. 1991, 21:2767-2774.
8. Barge R.M., Osanto S., Marijt W.A., Starrenburg C.W., Fibbe W.E., Nortier J.W., Falkenburg J.H., Willemze R. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp. Hematol. 2003, 31:865-872.
9. Barge R.M., Starrenburg C.W., Falkenburg J.H., Fibbe W.E., Marijt E.W., Willemze R. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience. Bone Marrow Transpl. 2006, 37:1129-1134.
10. Barrett A.J. Mechanisms of the graft-versus-leukemia reaction. Stem Cells 1997, 15:248-258.
11. Bastien J.P., Roy J., Roy D.C. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation. Semin. Oncol. 2012, 39:674-682.
12. Bleakley M., Heimfeld S., Loeb K.R., Jones L.A., Chaney C., Seropian S., Gooley T.A., Sommermeyer F., Riddell S.R., Shlomchik W.D. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J. Clin. Invest. 2015, 125:2677-2689.
13. Bleakley M., Otterud B.E., Richardt J.L., Mollerup A.D., Hudecek M., Nishida T., Chaney C.N., Warren E.H., Leppert M.F., Riddell S.R. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood 2010, 115:4923-4933.
14. D'Orsogna L.J., Roelen D.L., Doxiadis I.I., Claas F.H. Alloreactivity from human viral specific memory T-cells. Transpl. Immunol. 2010, 23:149-155.
15. de Bueger M., Bakker A., Van Rood J.J., Van der Woude F., Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J. Immunol. 1992, 149:1788-1794.
16. de Rijke B., van Horssen-Zoetbrood A., Beekman J.M., Otterud B., Maas F., Woestenenk R., Kester M., Leppert M., Schattenberg A.V., de W.T., van de Wiel-van Kemenade, Dolstra H. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J. Clin. Invest. 2005, 115:3506-3516.
17. den Haan J.M., Meadows L.M., Wang W., Pool J., Blokland E., Bishop T.L., Reinhardus C., Shabanowitz J., Offringa R., Hunt D.F., Engelhard V.H., Goulmy E. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998, 279:1054-1057.
18. den Haan J.M., Sherman N.E., Blokland E., Huczko E., Koning F., Drijfhout J.W., Skipper J., Shabanowitz J., Hunt D.F., Engelhard V.H. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995, 268:1476-1480.
19. Eefting M., Halkes C.J., de Wreede L.C., van Pelt C.M., Kersting S., Marijt E.W., von dem Borne P.A., Willemze R., Veelken H., Falkenburg J.H. Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Bone Marrow Transpl. 2014, 49:320.
20. Eefting M., von dem Borne P.A., de Wreede L.C., Halkes C.J., Kersting S., Marijt E.W., Veelken H., Falkenburg J.H. Intentional donor lymphocyte induced limited acute graft versus host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation. Haematologica 2014, 99:751-758.
21. Falkenburg J.H., Warren E.H. Graft versus leukemia reactivity after allogeneic stem cell transplantation. Biol. Blood Marrow Transpl. 2011, 17:S33-S38.
22. Farber D.L., Ahmadzadeh M. Dissecting the complexity of the memory T cell response. Immunol. Res. 2002, 25:247-259.
23. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
24. Fuji S., Kapp M., Einsele H. Alloreactivity of virus-specific T cells: possible implication of graft-versus-host disease and graft-versus-leukemia effects. Front Immunol. 2013, 4:330.
25. Greiner J., Li L., Ringhoffer M., Barth T.F., Giannopoulos K., Guillaume P., Ritter G., Wiesneth M., Dohner H., Schmitt M. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 2005, 106:938-945.
26. Griffioen M., van der Meijden E.D., Slager E.H., Honders M.W., Rutten C.E., van Luxemburg-Heijs S.A., von dem Borne P.A., Van Rood J.J., Willemze R., Falkenburg J.H. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3837-3842.
27. Haanen J.B., Baars A., Gomez R., Weder P., Smits M., de Gruijl T.D., von Blomberg B.M., Bloemena E., Scheper R.J., van Ham S.M., Pinedo H.M., van den Eertwegh A.J. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 2006, 55:451-458.
28. Handgretinger R. Negative depletion of CD3(+) and TcRalphabeta(+) T cells. Curr. Opin. Hematol. 2012, 19:434-439.
29. Holtick U., Chemnitz J.M., Shimabukuro-Vornhagen A., Theurich S., Chakupurakal G., Krause A., Fiedler A., Luznik L., Hellmich M., Wolf D., Hallek M., von Bergwelt-Baildon M., Scheid C. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur. J. Haematol. 2015, (in press).
30. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., Rimm A.A., Ringden O., Rozman C., Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
31. Jahn L., Hombrink P., Hassan C., Kester M.G., van der Steen D.M., Hagedoorn R.S., Falkenburg J.H., van Veelen P.A., Heemskerk M.H. Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b. Blood 2015, 125:949-958.
32. Jedema I., Meij P., Steeneveld E., Hoogendoorn M., Nijmeijer B.A., van de Meent M., van Luxemburg-Heijs S.A., Willemze R., Falkenburg J.H. Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay. Clin. Cancer Res. 2007, 13:636-643.
33. Kanda J., Lopez R.D., Rizzieri D.A. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int. J. Hematol. 2011, 93:586-593.
34. Khalil D.N., Budhu S., Gasmi B., Zappasodi R., Hirschhorn-Cymerman D., Plitt T., De H.O., Zamarin D., Holmgaard R.B., Murphy J.T., Wolchok J.D., Merghoub T. The new era of cancer immunotherapy: manipulating T-cell activity to overcome malignancy. Adv. Cancer Res. 2015, 128:1-68.
35. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
36. Kronig H., Hofer K., Conrad H., Guilaume P., Muller J., Schiemann M., Lennerz V., Cosma A., Peschel C., Busch D.H., Romero P., Bernhard H. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int. J. Cancer 2009, 125:649-655.
37. Leen A.M., Bollard C.M., Mendizabal A.M., Shpall E.J., Szabolcs P., Antin J.H., Kapoor N., Pai S.Y., Rowley S.D., Kebriaei P., Dey B.R., Grilley B.J., Gee A.P., Brenner M.K., Rooney C.M., Heslop H.E. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013, 121:5113-5123.
38. Locatelli F., Bauquet A., Palumbo G., Moretta F., Bertaina A. Negative depletion of alpha/beta+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunol. Lett. 2013, 155:21-23.
39. Macedo C., Orkis E.A., Popescu I., ElinoffB.D., Zeevi A., Shapiro R., Lakkis F.G., Metes D. Contribution of naive and memory T-cell populations to the human alloimmune response. Am. J. Transpl. 2009, 9:2057-2066.
40. Macesic N., Langsford D., Nicholls K., Hughes P., Gottlieb D.J., Clancy L., Blyth E., Micklethwaite K., Withers B., Majumdar S., Fleming S., Sasadeusz J. Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient. Am. J. Transpl. 2015, 15:827-832.
41. Markey K.A., MacDonald K.P., Hill G.R. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood 2014, 124:354-362.
42. Matsushita M., Yamazaki R., Ikeda H., Mori T., Sumimoto H., Fujita T., Okamoto S., Ikeda Y., Kawakami Y. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy. Br. J. Haematol. 2006, 132:56-65.
43. Meij P., Jedema I., Van Der Hoorn M.A., Bongaerts R., Cox L., Wafelman A.R., Marijt E.W., Willemze R., Falkenburg J.H. Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study. Haematologica 2012, 97:1205-1208.
44. Melenhorst J.J., Leen A.M., Bollard C.M., Quigley M.F., Price D.A., Rooney C.M., Brenner M.K., Barrett A.J., Heslop H.E. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010, 116:4700-4702.
45. Melenhorst J.J., Scheinberg P., Williams A., Ambrozak D.R., Keyvanfar K., Smith M., McCoy J.P., Hensel N.F., Douek D.C., Barrett A.J. Alloreactivity across HLA barriers is mediated by both naive and antigen-experienced T cells. Biol. Blood Marrow Transpl. 2011, 17:800-809.
46. Meyer R.G., Wagner E.M., Konur A., Bender K., Schmitt T., Hemmerling J., Wehler D., Hartwig U.F., Roosnek E., Huber C., Kolbe K., Herr W. Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation. Bone Marrow Transpl. 2010, 45:668-674.
47. Mielke S., McIver Z.A., Shenoy A., Fellowes V., Khuu H., Stroncek D.F., Leitman S.F., Childs R., Battiwalla M., Koklanaris E., Haggerty J., Savani B.N., Rezvani K., Barrett A.J. Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol. Blood Marrow Transpl. 2011, 17:1855-1861.
48. Munz C., Obst R., Osen W., Stevanovic S., Rammensee H.G. Alloreactivity as a source of high avidity peptide-specific human CTL. J. Immunol. 1999, 162:25-34.
49. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58:3491-3494.
50. Nash R.A., Storb R. Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL. Curr. Opin. Immunol. 1996, 8:674-680.
51. Ni K., O'Neill H.C. The role of dendritic cells in T cell activation. Immunol. Cell Biol. 1997, 75:223-230.
52. Obst R., Munz C., Stevanovic S., Rammensee H.G. Allo- and self-restricted cytotoxic T lymphocytes against a peptide library: evidence for a functionally diverse allorestricted T cell repertoire. Eur. J. Immunol. 1998, 28:2432-2443.
53. Oostvogels R., Lokhorst H.M., Minnema M.C., van E.M., van den Oudenalder K., Spierings E., Mutis T., Spaapen R.M. Identification of minor histocompatibility antigens based on the 1000 genomes project. Haematologica 2014, 99:1854-1859.
54. Orti G., Lowdell M., Fielding A., Samuel E., Pang K., Kottaridis P., Morris E., Thomson K., Peggs K., Mackinnon S., Chakraverty R. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation. Transplantation 2009, 88:1312-1318.
55. Pont M.J., Hobo W., Honders M.W., van Luxemburg-Heijs S.A., Kester M.G., van Oeveren-Rietdijk A.M., Schaap N., de Boer H.C., van Bergen C.A., Dolstra H., Falkenburg J.H., Griffioen M. LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application. Haematologica 2015, 100:e419-e422. (in press).
56. Reddy P., Maeda Y., Liu C., Krijanovski O.I., Korngold R., Ferrara J.L. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat. Med. 2005, 11:1244-1249.
57. Rezvani K., Brenchley J.M., Price D.A., Kilical Y., Gostick E., Sewell A.K., Li J., Mielke S., Douek D.C., Barrett A.J. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin. Cancer Res. 2005, 11:8799-8807.
58. Riddell S.R., Berger C., Murata M., Randolph S., Warren E.H. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev. 2003, 17:153-162.
59. Riddell S.R., Murata M., Bryant S., Warren E.H. Minor histocompatibility antigens-targets of graft versus leukemia responses. Int. J. Hematol. 2002, 76(Suppl. 2):155-161.
60. Rist M., Smith C., Bell M.J., Burrows S.R., Khanna R. Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-/nonself-recognition. Blood 2009, 114:2244-2253.
61. Rotzschke O., Falk K., Faath S., Rammensee H.G. On the nature of peptides involved in T cell alloreactivity. J. Exp. Med. 1991, 174:1059-1071.
62. Rutten C.E., van Luxemburg-Heijs S.A., Griffioen M., Marijt E.W., Jedema I., Heemskerk M.H., Posthuma E.F., Willemze R., Falkenburg J.H. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia 2008, 22:1387-1394.
63. Rutten C.E., van Luxemburg-Heijs S.A., Halkes C.J., van Bergen C.A., Marijt E.W., Oudshoorn M., Griffioen M., Falkenburg J.H. Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease. Biol. Blood Marrow Transpl. 2013, 19:40-48.
64. Sadovnikova E., Jopling L.A., Soo K.S., Stauss H.J. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur. J. Immunol. 1998, 28:193-200.
65. Savage P., Gao L., Vento K., Cowburn P., Man S., Steven N., Ogg G., McMichael A., Epenetos A., Goulmy E., Stauss H.J. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 2004, 103:4613-4615.
66. Scheibenbogen C., Letsch A., Thiel E., Schmittel A., Mailaender V., Baerwolf S., Nagorsen D., Keilholz U. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002, 100:2132-2137.
67. Sebzda E., Mariathasan S., Ohteki T., Jones R., Bachmann M.F., Ohashi P.S. Selection of the T cell repertoire. Annu. Rev. Immunol. 1999, 17:829-874.
68. Shook D.R., Triplett B.M., Eldridge P.W., Kang G., Srinivasan A., Leung W. Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability. Pediatr. Blood Cancer 2015, 62:666-673.
69. Smyth M.J., Godfrey D.I., Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2001, 2:293-299.
70. Spaapen R.M., de Kort R.A., van den Oudenalder K., van E.M., Bloem A.C., Lokhorst H.M., Mutis T. Rapid identification of clinical relevant minor histocompatibility antigens via genome-wide zygosity-genotype correlation analysis. Clin. Cancer Res. 2009, 15:7137-7143.
71. Spaapen R.M., Lokhorst H.M., van den Oudenalder K., Otterud B.E., Dolstra H., Leppert M.F., Minnema M.C., Bloem A.C., Mutis T. Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. J. Exp. Med. 2008, 205:2863-2872.
72. Spierings E. Minor histocompatibility antigens: past, present, and future. Tissue Antigens 2014, 84:347-360.
73. Starr T.K., Jameson S.C., Hogquist K.A. Positive and negative selection of T cells. Annu. Rev. Immunol. 2003, 21:139-176.
74. Stevanovic S., van Bergen C.A., van Luxemburg-Heijs S.A., van der Zouwen B., Jordanova E.S., Kruisselbrink A.B., van de Meent M., Harskamp J.C., Claas F.H., Marijt E.W., Zwaginga J.J., Halkes C.J., Jedema I., Griffioen M., Falkenburg J.H. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. Blood 2013, 122:1963-1973.
75. Storek J., Mohty M., Boelens J.J. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transpl. 2015, 21:959-970.
76. Stumpf A.N., van der Meijden E.D., van Bergen C.A., Willemze R., Falkenburg J.H., Griffioen M. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Blood 2009, 114:3684-3692.
77. Touzot F., Neven B., Dal-Cortivo L., Gabrion A., Moshous D., Cros G., Chomton M., Luby J.M., Terniaux B., Magalon J., Picard C., Blanche S., Fischer A., Cavazzana M. CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: a preliminary study. J. Allergy Clin. Immunol. 2015, 135:1303-1309.
78. van den Ancker W., Ruben J.M., Westers T.M., Wulandari D., Bontkes H.J., Hooijberg E., Stam A.G., Santegoets S.J., Ossenkoppele G.J., de G.T., van de Loosdrecht A. Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission: implications for immunotherapy. Oncoimmunology 2013, 2:e23971.
79. van der Zouwen B., Kruisselbrink A.B., Jordanova E.S., Rutten C.E., von dem Borne P.A., Falkenburg J.H., Jedema I. Alloreactive effector T-cells require the local formation of a proinflammatory environment to allow crosstalk and high avidity interaction with non-hematopoietic tissues to induce GvHD reactivity. Biol. Blood Marrow Transpl. 2012, 18:1353-1367.
80. van Loenen M.M., de B.R., van L.E., Meij P., Jedema I., Falkenburg J.H., Heemskerk M.H. A good manufacturing practice procedure to engineer donor virus-specific T-cells into potent anti-leukemic effector cells. Haematologica 2014, 99:759-768.
81. van Duin M., Broyl A., de K.Y., Goldschmidt H., Richardson P.G., Hop W.C., van der Holt B., Joseph-Pietras D., Mulligan G., Neuwirth R., Sahota S.S., Sonneveld P. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica 2011, 96:1662-1669.
82. Vickers M.A., Wilkie G.M., Robinson N., Rivera N., Haque T., Crawford D.H., Barry J., Fraser N., Turner D.M., Robertson V., Dyer P., Flanagan P., Newlands H.R., Campbell J., Turner M.L. Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br. J. Haematol. 2014, 167:402-410.
83. Viret C., Janeway C.A. MHC and T cell development. Rev. Immunogenet. 1999, 1:91-104.
84. Weber G., Gerdemann U., Caruana I., Savoldo B., Hensel N.F., Rabin K.R., Shpall E.J., Melenhorst J.J., Leen A.M., Barrett A.J., Bollard C.M. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia 2013, 27:1538-1547.
85. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.